233 related articles for article (PubMed ID: 35915542)
1. Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
Huang YB; Li WL; Sun M; Duan X; Wang YT; Zhang LX; Xin ZH; Yun ZF; Fan B; Li XC
Asian J Androl; 2023; 25(3):366-374. PubMed ID: 35915542
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between Androgen Deprivation Therapy for Prostate Cancer and Risk of SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.
Kim DK; Park JJ; Yang WJ; Doo SW; Kim JH
J Korean Med Sci; 2022 Aug; 37(31):e237. PubMed ID: 35942555
[TBL] [Abstract][Full Text] [Related]
3. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
Sari Motlagh R; Abufaraj M; Karakiewicz PI; Rajwa P; Mori K; Mun DH; Shariat SF
World J Urol; 2022 Apr; 40(4):907-914. PubMed ID: 34477955
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
5. Effects of Androgen Deprivation Therapy on COVID-19 in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
Karimi A; Nowroozi A; Alilou S; Amini E
Urol J; 2021 Jul; 18(6):577-584. PubMed ID: 34302737
[TBL] [Abstract][Full Text] [Related]
6. Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
Jiménez-Alcaide E; García-Fuentes C; Hernández V; De la Peña E; Pérez-Fernández E; Castro A; Caballero-Perea B; Guijarro A; Llorente C
Prostate; 2021 Dec; 81(16):1349-1354. PubMed ID: 34517429
[TBL] [Abstract][Full Text] [Related]
7. [Prostate cancer, androgen deprivation, and risk of COVID-19 infection : A systematic review and meta-analysis].
Manolache NG; Mjaess G; Diamand R; Albisinni S; Roumeguère T
Prog Urol; 2022 Dec; 32(16):1421-1430. PubMed ID: 36163317
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
[TBL] [Abstract][Full Text] [Related]
9. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to SARS-Cov-2 infection and risk for severe COVID-19 in patients with prostate cancer on androgen deprivation therapy.
Gedeborg R; Loeb S; Styrke J; Kiiski-Berggren R; Garmo H; Stattin P
Int J Cancer; 2022 Dec; 151(11):1925-1934. PubMed ID: 35802468
[TBL] [Abstract][Full Text] [Related]
11. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
[TBL] [Abstract][Full Text] [Related]
12. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
13. Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review.
Caffo O; Messina M; Veccia A; Kinspergher S; Maines F; Messina C
Crit Rev Oncol Hematol; 2021 Nov; 167():103491. PubMed ID: 34626792
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Crawley D; Adolfsson J; Rudman S; Van Hemelrijck M
PLoS One; 2015; 10(3):e0117344. PubMed ID: 25794005
[TBL] [Abstract][Full Text] [Related]
15. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer.
Gedeborg R; Lindhagen L; Loeb S; Styrke J; Garmo H; Stattin P
Scand J Urol; 2022 Apr; 56(2):104-111. PubMed ID: 34939533
[TBL] [Abstract][Full Text] [Related]
17. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.
Nead KT; Sinha S; Yang DD; Nguyen PL
Urol Oncol; 2017 Nov; 35(11):664.e1-664.e9. PubMed ID: 28803700
[TBL] [Abstract][Full Text] [Related]
18. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2.
Klein EA; Li J; Milinovich A; Schold JD; Sharifi N; Kattan MW; Jehi L
J Urol; 2021 Feb; 205(2):441-443. PubMed ID: 32897764
[TBL] [Abstract][Full Text] [Related]
20. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
